The number one reason that drugs fail in late phase clinical trials is hepatotoxicity. This suggests that data produced at the preclinical stage was not predictive. Scientists at PheonixSongs Biologicals have developed an innovative cell culture model that they hope will take a step towards solving this issue. Marsha Roach, Executive Vice President of PheonixSongs Biologicals, tells The Scientists’ Channel about the company’s revolutionary new solution for scientists working with hepatocytes and how her team successfully cultures different cells from multiple human tissues.